In Springfield, Illinois lawmakers have 11 days left in their spring session to evaluate a proposal for a state panel to review prescription drug costs and accessibility. This proposed legislation aims to establish a Prescription Drug Affordability Board (PDAB) as part of broader Democratic efforts to address the ongoing affordability crisis in Illinois and nationwide. Opponents argue the panel may not effectively reduce prices and could introduce unnecessary bureaucracy.
On Wednesday, the House Executive Committee passed the bill 8-4 along party lines. It now awaits a vote by the full House. Supporters believe the board could help control escalating drug costs, echoing federal initiatives under recent Biden-era policies. State Representative Nabeela Syed, a Democrat from Palatine, is the primary sponsor. She described the bill as “heavily negotiated” during a committee hearing. The bill’s latest version was filed after a previous attempt stalled.
If the bill passes, the board, composed of five members appointed by the governor, could evaluate and set payment limits on prescription drug prices. Pharmaceutical companies would have the opportunity to justify their prices before these caps are set. A key focus is improving access in rural and low-income communities. Under Syed’s bill, the Medicare-negotiated prices under the 2022 Inflation Reduction Act would become the maximum payment limits for all Illinois consumers. Some programs, like Medicaid, would need to opt in separately.
Medicare’s recent negotiations reduced costs for several high-cost drugs. For example, the price for Januvia, a diabetes medication, decreased from $527 to $113 for a 30-day supply, while Enbrel, used for rheumatoid arthritis, dropped from $7,106 to $2,355.
According to Anusha Thotakura, from Citizen Action/Illinois, the state overpays for these drugs by more than $190 million. Although opponents question this figure, the disparity highlights an issue worth addressing.
Under the bill, board members must have expertise in healthcare, pharmacy, or clinical medicine but cannot have ties to manufacturers. Their terms would last five years, with initial appointments staggered. Decisions could be appealed and reviewed judicially. The Illinois attorney general’s office could enforce the board’s actions, and legislative processes could address any law shortcomings.
Approximately a dozen states operate similar PDABs, some with broader authority than Illinois’ proposal. States like Colorado and Maryland have boards authorized to set drug pricing limits. The Pharmaceutical Research and Manufacturers of America opposes the bill, citing no measurable savings from similar boards. Peter Fotos, a representative from PhRMA, believes applying the Medicare pricing framework at the state level is unsuitable.
Deputy Republican Leader Ryan Spain raised concerns about the board’s operations, including its lack of affiliation with a state agency. Syed argued the board could operate independently with an estimated operating cost of $750,000 and saw no need for departmental housing.
Governor J.B. Pritzker’s office is reviewing the proposal without publicly declaring support. Separately, the legislature passed another bill targeting affordability, banning “junk fees” in pricing and requiring all mandatory fees to be displayed in advertised prices. The Senate approved it 46-12, and it now awaits Pritzker’s signature.
Leave a Reply